Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study shows how streptococcal bacteria can be used to fight colon cancer

21.05.2014

Researchers at Western University (London, Canada) have shown how the bacteria primarily responsible for causing strep throat can be used to fight colon cancer.


Western University researchers Dr. David Hess and Dr. John McCormick and lead author Kelcey Patterson show how the bacteria primarily responsible for causing strep throat can be used to fight colon cancer. By engineering a streptococcal bacterial toxin to attach itself to tumor cells, they are forcing the immune system to recognize and attack the cancer.

Credit: Schulich School of Medicine & Dentistry, Western University

By engineering a streptococcal bacterial toxin to attach itself to tumour cells, they are forcing the immune system to recognize and attack the cancer.

Kelcey Patterson, a PhD Candidate at Western and the lead author on the study, showed that the engineered bacterial toxin could significantly reduce the size of human colon cancer tumours in mice, with a drastic reduction in the instances of metastasis. By using mouse models that are stripped of their immune system, they were able to create a 'humanized mouse' – one that would not only grow human colon cancer cells, but would also support a human immune system, to test the anti-cancer immunotherapy.

The work was directed by John McCormick, PhD, an Associate Professor in the Department of Microbiology and Immunology and Scientist at the Lawson Health Research Institute. "Our team has been studying these bacterial toxins called 'superantigens' for their role in bacterial infections. But we are now utilizing the power of these toxins to re-direct the immune system to go after cancer cells."

McCormick says their research provides important pre-clinical evidence that this may work in humans. "This work represents a 'next-generation immunotoxin' that we hope will eventually lead to a new class of cancer therapeutic."

The research was funded by the Canadian Institutes of Health Research. Jennifer Dixon Pittaro, Peter Bastedo, David Hess and Mansour Haeryfar all contributed to the paper entitled "Control of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 oncofetal antigen."

McCormick and his colleagues have now received a new grant from the Cancer Research Society to develop different toxin and antibody combinations to fight other types of cancer.

Kathy Wallis | Eurek Alert!
Further information:
http://www.uwo.ca

Further reports about: bacteria bacterial colon fight grow immune immunotoxin infections toxins

More articles from Health and Medicine:

nachricht 'Sugar-coated' microcapsule eliminates toxic punch of experimental anti-cancer drug
18.12.2014 | Johns Hopkins Medicine

nachricht Fine particulate air pollution linked with increased autism risk
18.12.2014 | Harvard School of Public Health

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Anzeige

Anzeige

Event News

Smart Cities

08.12.2014 | Event News

European Polymer Congress 2015 in Dresden/Germany

01.12.2014 | Event News

Regional economic cooperation in Central Asia

21.11.2014 | Event News

 
Latest News

Protection of the mouse gut by mucus depends on microbes

18.12.2014 | Life Sciences

How the Cell Keeps Misdelivered Proteins From Causing Damage in the Cell Nucleus

18.12.2014 | Life Sciences

How can one recognise a legal firework item?

18.12.2014 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>